Patent ID: 11938174
Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 6:
7. The method according to claim 1, further comprising administering an adjunct treatment additional biologically active agent effective for treating or delaying the progression of a disorder selected from the group consisting of neuromyelitis optica (NMO) or Devic's disease, single or recurrent events of longitudinally extensive transverse myelitis, bilateral simultaneous or recurrent optic neuritis, Asian optic-spinal multiple sclerosis, optic neuritis associated with systemic autoimmune disease, optic neuritis or myelitis associated with lesions in the specific brain areas of the hypothalamus, periventricular nucleus, or brainstem, and NMO-IgG negative NMO:AQP4 antibody-seronegative NMO.